IL139448A0 - Use of apo b secretion/mtp inhibitors - Google Patents

Use of apo b secretion/mtp inhibitors

Info

Publication number
IL139448A0
IL139448A0 IL13944800A IL13944800A IL139448A0 IL 139448 A0 IL139448 A0 IL 139448A0 IL 13944800 A IL13944800 A IL 13944800A IL 13944800 A IL13944800 A IL 13944800A IL 139448 A0 IL139448 A0 IL 139448A0
Authority
IL
Israel
Prior art keywords
apo
secretion
mtp inhibitors
mtp
inhibitors
Prior art date
Application number
IL13944800A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL139448A0 publication Critical patent/IL139448A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13944800A 1999-11-10 2000-11-02 Use of apo b secretion/mtp inhibitors IL139448A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16454799P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
IL139448A0 true IL139448A0 (en) 2001-11-25

Family

ID=22595001

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13944800A IL139448A0 (en) 1999-11-10 2000-11-02 Use of apo b secretion/mtp inhibitors

Country Status (11)

Country Link
EP (1) EP1099439A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2001172180A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010051558A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU6968700A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2324800A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5261534A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0004461A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL139448A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ508059A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20010705A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200006419B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161134A0 (en) 2002-02-28 2004-08-31 Japan Tobacco Inc Ester compound and medical use thereof
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
JP4782695B2 (ja) * 2004-10-25 2011-09-28 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
JPWO2012124744A1 (ja) * 2011-03-14 2014-07-24 大正製薬株式会社 含窒素縮合複素環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091102C (en) * 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DK0902785T3 (da) * 1996-04-30 2002-10-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 4'-trifluormethylbiphenyl-2-carboxylsyre-[2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]amid
KR100334567B1 (ko) * 1996-11-27 2002-05-03 디. 제이. 우드, 스피겔 알렌 제이 아포 비-분비/엠티피 억제성 아미드
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Also Published As

Publication number Publication date
NZ508059A (en) 2002-11-26
HUP0004461A2 (hu) 2001-10-28
JP2001172180A (ja) 2001-06-26
CO5261534A1 (es) 2003-03-31
KR20010051558A (ko) 2001-06-25
EP1099439A3 (en) 2003-03-26
HU0004461D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-01-29
PE20010705A1 (es) 2001-07-11
EP1099439A2 (en) 2001-05-16
AU6968700A (en) 2001-05-17
HUP0004461A3 (en) 2004-04-28
CA2324800A1 (en) 2001-05-10
ZA200006419B (en) 2002-05-08

Similar Documents

Publication Publication Date Title
PL362546A1 (en) Benzamide compounds as apo b secretion inhibitors
GB9900416D0 (en) Inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
IL148698A0 (en) INHIBITORS OF FACTOR Xa
IL148719A0 (en) Kinase inhibitors as therapeutic agents
DE60027761D1 (de) Komprimierte zubereitung enthaltend nichtsteroidale entzündungshemmer
AU8969601A (en) New use of lipase inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
IL139450A0 (en) Methods of administering apo b-secretion/mtp inhibitors
IL156479A0 (en) Substituted-8-arylquinoline phosphodiesterase-4 inhibitors
IL139448A0 (en) Use of apo b secretion/mtp inhibitors
EP1235577A4 (en) PROTEASE INHIBITORS
EP1153022A4 (en) PROTEASE INHIBITORS
EP1232155A4 (en) PROTEASE INHIBITORS
IL139449A0 (en) Use of apo b secretion/mtp inhibitors
EP1229912A4 (en) PROTEASE INHIBITORS
EP1229914A4 (en) PROTEASE INHIBITORS
EP1229915A4 (en) PROTEASE INHIBITORS
EP1231921A4 (en) PROTEASE INHIBITORS
GB2355657B (en) Inhibitors Of Gastric Acid Secretion
EP1229911A4 (en) PROTEASE INHIBITORS
EP1161237A4 (en) PROTEASE INHIBITORS
EP1351930A4 (en) PROTEASE INHIBITORS
EP1173429A4 (en) PROTEASE INHIBITORS